Effectiveness of Menosan® in the treatment of menopausal complaints: a double-blind, randomized, placebo-controlled, clinical trial
This randomized, double-blind and placebo-controlled trial was conducted in 80 menopausal women (48-65 years) receiving either Menosan® tablets (3400 mg ethanolic extract of freshly harvested Salvia officinalis) or placebo for 4 weeks.
The results show that Menosan® reduced menopausal rating scale (MRS) score by 39.2% (p = 0.002 vs. placebo) and the hot flush severity score (HFS) by 55.3% reaching significance on week 3 (p = 0.028). Clinical effects of Menosan® correlated with relevant reduction of frontal lobe beta2 wave qEEG intensities. Menosan® within 4 weeks significantly reduced the somato-vegetative (e.g. hot flushes) and psychological MRS subscale (e.g. physical and mental exhaustion) (p < 0.05) without a significant effect on the genito-urinary subscale. Moreover, a positive impact was seen on sleep quality, discontent and fatigue (p < 0.05) compared with placebo.
Therefore, the results support the use of Menosan® for the specific treatment of a wide range of somato-vegetative and psychological symptoms as experienced by menopausal women.
Wilfried D, Nina CDG, Silvia B. Effectiveness of Menosan® Salvia officinalis in the treatment of a wide spectrum of menopausal complaints. A double-blind, randomized, placebo-controlled, clinical trial. Heliyon. 2021 Feb 10;7(2):e05910.